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Abstract
Objective—The Peroxisome Proliferator Activated Receptor-gamma (PPARγ) protein is a nuclear
transcriptional activator with importance in diabetes management as the molecular target for the
thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of
PPARγ agonists may retard the development of atherosclerosis. However, recent clinical data has
suggested that at least one TZD may increase the risk of myocardial infarction and death from
cardiovascular disease. In this study, we used a genetic approach to disrupt PPARγ signaling to probe
the protein's role in smooth muscle cell (SMC) responses that are important for atherosclerosis.
Results/Methods—SMC isolated from transgenic mice harboring the dominate-negative P465L
mutation in PPARγ (PPARγL/+) exhibited greater proliferation and migration then did wild-type
cells. Upregulation of ETS-1, but not ERK activation, correlated with enhanced proliferative and
migratory responses PPARγL/+ SMCs. Following arterial injury, PPARγL/+ mice had a ~ 4.3-fold
increase in the development of intimal hyperplasia.
Conclusion—These findings are consistent with a normal role for PPARγ in inhibiting SMC
migration and proliferation in the context of restenosis or atherosclerosis.
INTRODUCTION
PPARγ, a dynamic nuclear transcriptional regulator, has well characterized roles in adipocyte
differentiation1, lipid metabolism2 and insulin sensitivity3, 4. Clinically PPARγ is the
molecular target of the insulin sensitizing thiazolidinedione (TZD) class of drugs that includes
rosiglitazone and pioglitazone5. TZD 6 and other PPARγ agonists 7 effectively increase insulin
sensitivity in type 2 diabetic patients. Many preclinical and clinical studies have suggested that
PPARγ agonists protect against the development of atherosclerosis 8–11 and reduce the
development of intimal hyperplasia9, 12–14. In the PROACTIVE trial, the PPARγ agonist
pioglitazone had beneficial effects on the combined secondary endpoints of myocardial
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infarction, stroke and death15. However a recent meta-analysis suggested that the use of the
PPARγ agonist rosiglitazone for the treatment of diabetes was associated with an increase in
risk of myocardial infarction and a trend towards a higher risk of cardiovascular death 16.
Endogenous ligands for PPARγ include unsaturated and oxidized fatty acids, eicosanoids,
prostaglandins and possibly lysophospholipids. The putative PPARγ agonist lysophosphatidic
acid (LPA) accelerates neointimal formation after vessel injury in rodents in a PPARγ-
dependent manner17, suggesting that activation of PPARγ may promote the development of
intimal hyperplasia. However, at present, the role that PPARγ plays in regulating vascular
responses that underlie atherosclerosis and restenosis remain incompletely understood.
Proliferation and migration of vascular smooth muscle cells (SMCs) are key events in the
development of intimal hyperplasia that occurs in the context of atherosclerosis and
restenosis18 . PPARγ is present in vascular SMCs19, and the atheroprotective effects of
PPARγ ligands have been proposed to relate in part to beneficial effects on SMC biology.
Indeed, studies have shown that TZDs inhibit vascular SMC proliferation 12, 13 and migration
12, 13, 20, while increasing apoptosis21. It is not clear whether this is a direct effect of TZDs on
PPARγ or an “off-target” effect of the drugs, as most studies have inferred a role for PPARγ
in atherosclerosis on the basis of results with pharmacologic interventions. Homozygous
deficiency of PPARγ is embryonic lethal 1. Atherosclerosis and the development of intimal
hyperplasia in a vascular SMC-specific PPARγ knock-out mouse have not been reported.
However, there is genetic evidence to support a role for PPARγ in SMC biology. For example,
a generalized PPARγ knock-out model was created by breeding floxed PPARγ mice to Mox2-
Cre mice to inactivate PPARγ in the embryo but not in trophoblasts 22. The resulting mice have
hypotension and impaired SMC contraction. PPARγ variants with dominant negative function
have been documented in families of humans with insulin resistance, type II diabetes and
hypertension. Dominant negative loss-of-function PPARγ mutations have also been introduced
into mice to phenocopy abnormalities identified in humans. In humans, the substitution of a
leucine for proline at amino acid 465 (P465L) is associated with severe insulin-resistance and
significantly reduced PPARγ activity 23. The homologous mutation in mice, P467L, causes
hypertension, abnormal fat distribution but not insulin resistance 24, and cerebral vascular
dysfunction 25. Thus, mice with the PPARγ-P465L mutation (PPARγL/+ mice) may be a useful
model to examine the role of PPARγ signaling in SMC function.
In the present study, we examined the response of primary cultures of SMCs obtained from
aortas of mice harboring the PPARγL/+ mutation or sibling controls. We report increases in
proliferation and migration that translated into enhanced neointimal hyperplasia following
vascular injury in vivo.
METHODS
Animals
The generation and genotyping of 129/SvEv mice containing the P465L mutation in PPARγ
(PPARγL/+) mutation has been previously described 24, 25. To minimize background-specific
effects, the PPARγL/+ mice on the 129/SvEv background were crossed with female C57BL/6J
mice from Jackson laboratories to generate F1 mice with the same complement of genes varying
only in the presence (PPARγL/+) or absence (PPARγ+/+) of the P465L mutation. Carotid
ligation was performed in eight week old wild type PPARγ+/+ and PPARL/+ sibling matched
mice and analyzed as previously described 26, 27. Carotid arteries were stained with combined
Mason's Trichrome and elastin stain. Serial sections taken at 0.4 mm intervals from the ligation
for histomorphometric analysis.
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Vascular Smooth Muscle Cells
Aortas from sibling-paired mice aged 4 and 6 weeks old were digested in collagenase (175 U/
ml; Worthington, NJ) and then adventitial tissue removed with by gentle tractios using forceps.
The adventitia-free aorta was incubated overnight in a Dulbecco's Modified Eagle Medium
(DMEM) containing 10% Fetal Bovine Serum (FBS), and then digested with elastase
(concentration 0.25mg/ml, Sigma, MO) and collagenase (175 U/ml) in Hank's Balanced Salt
Solution to generate isolated cells. Cells were cultured in DMEM containing 0.5 ng/ml EGF,
5 μg/ml insulin, 2 ng/ml bFGF, 10%FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin.
SMCs were isolated from endothelial cells by magnetic bead separation system (Invitrogen,
Carlsbad, CA) and cell purity verified by SM α-actin staining.
For proliferation assays, cells at 70% confluence were serum starved in a 0.1% FBS for 72
hours and then plated at a concentration of 5,000 cells/well on a 96-well plate. Cells were
treated with 0.1% BSA in PBS (vehicle), 20 ng/ml mouse platelet derived growth factor-BB
(PDGF-BB,Ray Biotech, GA), or 10% FBS. The number of viable cells was quantified after
24, 48, 72, and 96 through incubation for 2 hours in a WST-1 solution (Biochain, CA). WST-1
is cleaved by mitochondrial succinate-tetrazolium reductase in viable cells to form formazan
dye. The amount of formazan is proportional to the number of viable cells. After 2 hours of
incubation in WST-1, absorbance at 450 nm was measured. For ERK activity, cells were
washed with ice cold PBS and lysed (10 mM Tris-HCl pH 7.2, 1% Nonidet P-40, 158 mM
NaCl, 1 mM EDTA, 50 mM NaF, 1 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM
sodium orthovanadate, 10 mM sodium pyrophosphate). Total protein in clarified cell lysates
(16,000g × 10 min) was determined (BCA protein assay; Pierce, Rockford, IL) and equal
amounts loaded onto 10% SDS-PAGE. Immunoblotting was performed with antibodies to actin
(Santa Cruz Biotechnology, Santa Cruz, CA), ERK/phospho-ERK Thr202/Tyr204, and ETS-1
(Santa Cruz) and quantified using the Odyssey infrared imaging system (LI-COR, Lincoln,
NE). Equal sample loading was confirmed by Coomassie blue staining.
In the scratch migration assays, cells were grown to confluence and then serum starved for 72
hours at which time a 400 μm scratch was placed through the confluent layer of cells using the
end of a 200 μl pipette tip. After 12 hours, migration into the scratch was imaged through phase
contrast microscopy with a Leica DM IRB inverted microscope. Cells in at least three fields
were manually counted and the area occupied measured with NIH Image J software. In separate
experiments, chemotactic migration was assessed by placing serum starved cells (1.8 × 104
cells/well) in the upper well of a chamber of a multiwellchambers (Neuroprobe Inc.,
Gaithersburg, MD) with a polyvinylpyrrolidone-free polycarbonate filter (5 μm pore). The
bottom chamber was filled with DMEM containing 0.1% FBS and the indicated chemotactic
agent (1 μM LPA [18:1 LPA in 0.1% BSA; Avanti Polar Lipids], 10% FBS, 20 ng/ml PDGF)
or vehicle. The chamber was incubated for 12-h at 37°C in a CO2 incubator, at which time the
filter was removed from the chamber and the non-migrated cells were scraped from the upper
surface. The membranes were fixed, and the migrated cells stained with Diff-Quik® (VWR
Scientific Products, West Chester, PA). Digital images of the membranes were obtained with
a Nikon 80i microscope using a 20× objective (NA = 0.5). The total area (μm2) occupied by
migrated cells was determined with Metamorph imaging software.
For siRNA experiments, SMCs were placed in serum and antibiotic-free medium (10% (v/v)
FBS in DMEM) at least 2 h before transfection and incubated with approximately 100nM of
siRNA oligonucleotides to ETS-1 and scrambled control (Dharmacon, Lafayette, CO) and
1μl/cm2 plate of X- tremeGENE siRNA Transfection Reagent (Roche, Indianapolis, IN).
siGLO Green Transfection Indicator was used as a qualitative indicator of delivery. After 24
hours, the medium was changed to low or high glucose DMEM medium containing antibiotics
(10% (v/v) FBS, 1% (m/v) penicillin and streptomycin and the chemotactic migration assay
was performed as described above.
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In vitro experiments were performed a minimum of three times with cells prepared from at
least three different cohorts of animals. All results were expressed as mean ± standard error of
the mean (se). All data was analyzed using non-paired t-test or ANOVA, where indicated, using
Sigma-STAT software, version 3.5 (Systat Software, Inc. San Jose, CA). A p-value of less than
0.05 was considered significant.
RESULTS
PPARγL/+ vascular smooth muscle cells exhibit enhanced proliferation and migration
A key element in the development of neointima is the proliferation and migration of SMCs
from the vessel media to intima. Studies using synthetic PPARγ agonists such as TZDs have
identified a potential role for PPARγ as a regulator of SMC proliferation and migration. To
probe the normal role of PPARγ in SMC responses, we employed a genetic strategy in which
PPARγ activity was attenuated by the introduction of a dominant-negative PPARγ mutation
in mice. SMCs were isolated from aortas of wild-type mice or heterozygous knock-in mice
carrying the dominant negative P465L mutation in PPARγ (PPARγL/+) and their proliferative
properties examined. PPARγL/+ SMCs displayed a modest 1.6-fold increase in proliferation in
response to 10% FBS as compared to wild-type PPARγ+/+cells at 72 hours (P = 0.003;
Supplemental Figure 1). The enhanced proliferation was not observed in vehicle-treated
PPARγL/+ cells or in the presence of PDGF (Supplemental Figure 1).
PPARγL/+ SMCs also displayed enhanced wound closure in a scratch assay (Figure 1A).
Twelve hours after a single scratch injury, significantly more PPARγL/+ SMCs migrated into
the wound (108±4 PPARγL/+ cells versus 73±3 wild-type PPARγ+/+ cells, P = 0.002, Figure
1B) and they migrated a greater distance (132±7 μm for PPARγL/+ cells compared 101±7 μm
for PPARγ+/+ cells; P = 0.035; Figure 2C). PDGF (20 ng/ml) increased the number of
PPARγ+/+ cells and the distance they migrated and nearly rescued the defect in the
PPARγL/+ cells. In the presence of PDGF, 130±4 PPARγL/+ cells and 110±2 PPARγ+/+ cells
(P = 0.011) migrated a distance of 158±3 μm and 153±6 μm (P = 0.49), respectively (Figure
2C).
The behavior of wild-type PPARγ+/+ (Figure 2A) and mutant PPARγL/+ (Figure 2B) cells was
also measured in a chemotactic assay in which the cells migrated towards a gradient of FBS,
PDGF, or lysophosphatidic acid (LPA), which, in addition to its well-described actions at cell
surface receptors, has been proposed to also serve as a PPARγ agonist 28. In wild-type
PPARγ+/+ cells, migration increased 5.2 fold in the presence of FBS and 10-fold with LPA,
whereas migration increased ~20 fold with the combination of FBS and LPA (Figure 2C). In
comparison to wild-type cells, the migration of PPARγL/+ cells was 6.1-fold higher towards
FBS (P= 0.002, by ANOVA), 4-fold higher to PDGF (P= 0.004 by ANOVA), and 2.6-fold
higher to LPA (P = 0.002 by ANOVA).
Mitogen-activated protein kinase pathways involving ERK contribute to SMC proliferative
and migratory responses. We previously reported that SMC migration to FBS and LPA requires
ERK activity 27. In keeping with these observations, the MEK1 inhibitor PD 98059 reduced
chemotactic migration of wild-type PPARγ+/+ and PPARγL/+ SMCs by 62% and 58%,
respectively (Supplemental Figure 1). In addition, the TZDs rosiglitazone and pioglitazone
inhibited wild-type PPARγ+/+ cell migration by ~50% and 40%. Interestingly, rosiglitazone
but not pioglitazone partially blocked PPARγL/+ cell migration by ~40% (Supplemental Figure
1).
TZDs have been variably proposed to alter ERK activity in SMCs, with some studies suggesting
a role for TZDs in regulating cytosolic ERK 29 and other studies showing an effect downstream
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of cytosolic ERK 30, 31. Therefore, we examined the effects of the PPARγ P465L mutation on
ERK activation in SMC. In wild-type PPARγ+/+ cells, FBS elicited an increase in ERK activity
at 10 min that persisted for 60 min (Figure 3A). PDGF also increased ERK activity rapidly and
resulted in a slight, but sustained elevation in ERK activity at 6 hours (Figure 4B). LPA
stimulated a rapid increase in ERK phosphorylation that was maximal at 5 – 10 min (Figure
3C) and a second phase of late ERK activation. Biphasic ERK activation also occurs in
thrombin stimulated SMC, where the second phase of ERK activation is triggered by HB-EGF
expression32. No substantial differences were observed in ERK activation in mutant
PPARγL/+ cells in response to FBS (Figure 4A), PDGF (Figure 3B), or LPA (Figure 3C). Based
on these results, the enhanced migration observed in the presence of the PPARγ dominant
negative mutation is unlikely to be the result of increased ERK activity. Others have reported
that PPARγ agonists prevent SMC migration by acting downstream of ERK to block expression
of ETS-1 31. ETS-1 also regulates the ability of PPARγ agonists to inhibit telomerase activity
in SMC 33. We therefore examined the effects of the dominant-negative PPARγ P465L
mutation on ETS-1. Following stimulation with FBS or PDGF, PPARγL/+ cells upregulated
ETS-1 to a significantly greater extent at earlier (~ 1 hour; P= 0.028) and later (~12 hours; P=
0.041) time points than did PPARγ+/+ cells (Figure 4A). Moreover, down regulation of ETS1
using RNA-dependent gene silencing (siRNA) blunted the enhanced PPARγL/+ cell migration
(Figure 4B)
PPARγL/+ mice show increased neointimal formation during vascular remodeling
To determine if the enhanced SMC proliferation and migration observed in PPARγL/+ SMC
in culture also occurs in vivo, we examined the response to arterial injury in PPARγ+/+ and
PPARγL/+ mice using a well-characterized mouse model in which robust development of
intimal hyperplasia occurs 26. At four weeks following carotid injury, intimal hyperplasia
develops along the length of the vessel (Figure 5A and B). In response to injury, PPARγL/+
mice develop more extensive neointima with a statistically greater intima/media ratio (Figure
5A and 5B; n = 8 PPARγ+/+, n = 9 PPARγL/+). At 10 mm from the ligation, the PPARγL/+
vessels display a 4.3 fold increase in neointima formation compared to the wild-type
PPARγL/+ vessel (P = 0.005 by ANOVA). The difference in intima:media ratio persisted until
24 mm from the ligation (Figure 5B). No difference in lumen (P = 0.317; Figure 5C) or medial
(P = 0.447; Figure 5D) areas were observed between mice of different genotypes. Consistent
with the observations in isolated cells, ETS-1 expression was higher in PPARγL/+ vessels
following injury (Figure 6).
DISCUSSION
Studies in animal models have shown that PPARγ agonists inhibit atherosclerotic development
10. However, the precise role for PPARγ signaling in vascular SMCs remains unclear. In this
report, we used a strain of mice harboring a dominant-negative acting PPARγ allele that
suppresses endogenous PPARγ function24 to probe the normal role of PPARγ signaling in SMC
phenotypic modulation that is important for atherosclerosis and restenosis. SMCs with the
PPARγ P465L mutation display dramatically enhanced migration and a modest increase in
proliferation in in vitro assays. These in vitro observations appear relevant in vivo because mice
with the PPARγ P465L mutation exhibit exaggerated development of intimal hyperplasia
following arterial injury. Upregulation of ETS-1 correlates with the enhanced migration in
PPARγL/+ SMCs, and transient reduction of ETS-1 inhibited PPARγL/+ SMC migration. ETS-1
levels were also higher in PPARγL/+ arteries after injury. Our findings are consistent with
previous demonstrations that ETS-1 mediates the effects of PPARγ agonists on migration31
and telomerase activity33. Interestingly, although ERK activation contributes to SMC
migration, we did not observe substantial differences in ERK activation in WT and
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PPARγL/+ SMCs. Others have also suggested that the anti-migratory effects of TZDs occur
down-stream of ERK 31.
Our results are consistent with a normal role for PPARγ in attenuating injury-induced SMC
proliferation, migration, and vascular remodeling. Our findings are in agreement with previous
studies documenting inhibition of neointimal formation by TZD agonists in animal models
34 and a slowing of progression of carotid intima-media thickness by TZDs in individuals with
Type2 diabetes 35. The beneficial effects of TZDs in nondiabetic preclinical models and our
results in nondiabetic mice suggest that the reduction in intimal hyperplasia associated with
PPARγ activity is not simply a consequence of normalizing blood glucose and other metabolic
abnormalities of diabetes. Because the PPARγ P465L mutation may affect signaling through
other PPAR isoforms 9, we can not exclude a role of PPARα or PPARδ in regulating SMC
responses. However our results, when considered in the context of the beneficial effects of
TZDs, are most consistent with a central role of PPARγ in attenuating SMC proliferative and
migratory responses in the context of vascular injury. While our results suggest a direct role
for PPAR signaling in SMCs, effects in other vascular cells, such as monocytes and endothelial
cells, may also indirectly influence SMC function following arterial injury. Together with
published experiments using pharmacologic approaches, our observations in a genetic model
of altered PPARγ activity support a role for endogenous PPARγ in modulating important
pathophysiologic processes underlying restenosis and atherosclerosis.
Surprisingly, rosiglitazone but not pioglitazone was able to suppress migration and
proliferation in cells from mice with the PPARγ P465L mutation. The lack of effect of
pioglitazone was specific, in that under identical conditions, both pioglitazone and
rosiglitazone inhibited wild-type SMC migration and proliferation. These findings would be
consistent with rosiglitazone eliciting “off-target” effects that are not mediated by PPARγ. In
this context it is interesting to note that clinical trials have tended to show a beneficial vascular
effect of pioglitazone15 but not of rosiglitazone16. It is possible, however, that the PPARγL/+
cells have low levels of PPARγ activity that for unknown reasons are selectively enhanced by
rosiglitazone but not pioglitazone.
Our findings are also relevant to the role of the lysolipid mediator LPA in regulating SMC
responses. In addition to acting on G-protein coupled receptors, LPA has been proposed as an
endogenous agonist of PPARγ28. In contrast to the inhibitory effects on the development of
intimal hyperplasia reported with the TZD class of agonists, infusion of LPA into rodent carotid
arteries has been associated with the formation of neointimal hyperplasia in a PPARγ-
dependent manner17. We observed enhanced LPA-migration in SMC with the dominant-
negative loss-of-function PPARγL/+ mutation, which appears to be non-selective with regards
to agonists in that PPARγL/+ SMC migration to PDGF was also enhanced. Our results suggest
that LPA-, FBS- and PDGF-promoted chemotactic migration of SMCs is normally inhibited
by PPARγ-dependent pathways. Whether PPARγ mediates other effects of LPA on vascular
SMC function or regulates the effects of endogenous LPA is not known.
In conclusion, our findings are consistent with a normal role for PPARγ in attenuating SMC
migratory and proliferative properties which translate into beneficial vascular effects in terms
of limiting the development of neointima. If future studies substantiate the initial reports of an
association of at least one TZD with higher rates of adverse cardiovascular events, our results
might suggest that the adverse cardiovascular profile for TZDs are due either to “off-target”
effects or are the result of proatherothrombotic effects mediated by PPARγ agonism in other
blood and vascular cells.
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Figure 1. Enhanced wound closure in PPARγL/+ aortic SMC
SMCs were grown to confluence, serum starved, and then a 400 μm scratch was made through
the lawn of confluent cells. After 12 hours, the region containing the scratch was imaged. The
number of migrated cells was measured from digital images (A). Significantly more
PPARγ L/+ SMCs migrated into the scratch (P = 0.002). The addition of PDGF to the media
after scratch injury increased numbers of both PPARγ +/+ and PPARγ L/+ SMCs in the wound
at 12 hours. (B): PPARγ L/+ cells migrated further into the wound than did PPARγ +/+ cells in
the absence (P = 0.035) but not the presence of PDGF (P = 0.49). Values are presented as mean
± se.
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Figure 2. Enhanced migration in PPARγL/+ SMC
SMCs were stained with Diff-Quik® on the undersurface of a membrane with a 5 μm pore
following migration to media containing vehicle, 10% FBS, 20 ng/ml PDGF, or 1 μM LPA.
Representative images of migrated PPARγ +/+ SMCs (A) and PPARγ L/+ SMCs (B). The area
occupied by migrated cells is presented as mean ± se (C). Combined results from three
experiments are shown. *P<0.05 versus vehicle treatment by ANOVA. Values are presented
as mean ± se.
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Figure 3. Normal ERK activation in PPARγL/+ SMC
Time course of activation of ERK, as measured by phosphoERK/total ERK ratios, in cells
following exposure to 10% FBS (A), 20 ng/ml PDGF (B), or 1 μM LPA (C). Results are
presented as mean ± se and representative of three experiments with independent cultures of
SMCs of each genotype.
Meredith et al. Page 12













Figure 4. Alterations in ETS-1 in PPARγL/+ SMC may account for enhanced migration
(A) Time course of effects of 20 ng/ml PDGF on ETS-1 levels. Results are presented as mean
± se and are representative of three experiments. (B) Migration of PPARγ L/+ was performed
72h after transfection with scrambled control siRNA or siRNA to ETS-1. Images are
representative of results obtained in three experiments. Results are graphed as mean ± sd. * P
<0.05.
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Figure 5. Enhanced remodeling in PPARγL/+ mice in response to arterial injury
Injured vessels were sectioned, imaged and measured with Image J to quantify vessel intima
and media areas. Representative cross section of an injured PPARγ +/+ and PPARγ L/+ artery
at 10 mm from the ligation (A). Intima to media ratios (B), lumen areas (C) and media areas
(D) were calculated along the length of the vessel. Values are graphed as mean ± se.
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Figure 6. Upregulation of ETS-1 expression in PPARγL/+ arteries after injury
Immunohistochemistry for ETS-1 was performed on sections of injured vessels. Representative
cross section of an injured PPARγ +/+ and PPARγ L/+ artery are presented. The bar is 100 μm.
The average area of ETS-1 in 5 vessels of each genotype is graphed (mean ± se). *P <0.05
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